Inflammation in HLA-B27-associated Diseases

References

• Meuwissen S GM, Dekker-Saeys B J, Agenant D, et al. Ankylosing spondylitis and inflammatory bowel disease. I. Prevalence of inflammatory bowel disease in patients suffering from ankylosing spondylitis. Ann Rheum Dis 1978; 37: 30–2
   PubMed Web of Science ®Google Scholar
• Aho K, Leirisalo-Repo M, Repo H. Reactive arthritis. Clin Rheum Dis 1985; 11: 25–40
   PubMedGoogle Scholar
• Vasey F B, Deitz C, Fenske N A, Germain B F, Espinoza LR. Possible involvement of group A streptococci in the pathogenesis of psoriatic arthritis. J Rheumatol 1982; 9: 719–22
   PubMed Web of Science ®Google Scholar
• Ebringer A, Maines M, Praszynska T. Spondylarthritis, uveitis, HLA-B27 and klebsiella. Immunol Rev 1985; 86: 101–16
   PubMed Web of Science ®Google Scholar
• Eastmond C J, Calguneri M, Shinebaum R, Cooke E M, Wright V. A sequential study of the relationship between faecal Klebsiella aerogenes and the common clinical manifestations of ankylosing spondylitis. Ann Rheum Dis 1982; 41: 15–20
   Google Scholar
• Warren R E, Brewerton DA. Faecal carriage of klebsiella by patients with ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 1980; 39: 37–44
   PubMed Web of Science ®Google Scholar
• WHO Scientific Working Group: Enteric infections due to Campylobacter, yersinia, salmonella, and shigella. Bull WHO 1980; 58: 519–37
   PubMed Web of Science ®Google Scholar
• Vender R J, Marignani P. Salmonella colitis presenting as a segmental colitis resembling Crohn's disease. Dig Dis Sci 1983; 28: 848–51
   Google Scholar
• Vesterby A, Baandrup U, Jacobsen N O, et al. Campylobacter enterocolitis. An important differential diagnosis in ulcerative colitis. Acta Pathol Microbiol Scand Sect A 1983; 91: 31–3
   Google Scholar
• Ekberg O, Sjostrom B, Brahme F. Radiological findings in yersinia ileitis. Radiology 1977; 123: 15–9
   Google Scholar
• Hoogkamp-Korstanje J AA, De Koning J, Samsom JP. Incidence of human infection with Yersinia enterocolitica serotypes 03, 08, and 09 and the use of indirect immunofluorescence in diagnosis. J Infect Dis 1986; 153: 138–41
   PubMed Web of Science ®Google Scholar
• Hoogkamp-Korstanje J AA, De Koning J, Heesemann J. Persistence of Yersinia enterocolitica in man. Infection 1988; 16: 81–5
   PubMed Web of Science ®Google Scholar
• Schachter J, Barnes M G, Jones J P, Engelman E P, Meyer KF. Isolation of Bedsoniae from the joints of patients with Reiter's syndrome. Proc Soc Exp Biol Med 1966; 122: 283–5
   PubMed Web of Science ®Google Scholar
• Vilppula A H, Yli-Kerttula U I, Ahlroos A K, Terho PE. Chlamydial isolations and serology in Reiter's syndrome. Scand J Rheumatol 1981; 10: 181–5
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ohno O, Yamasaki K, Ikuta S, Hirohata K. Arthritis presumably caused by chlamydia in Reiter's syndrome. J Bone Joint Surg Am 1986; 68: 777–9
   PubMedGoogle Scholar
• Keat A, Thomas B, Dixey J, Osborn M, Sonnex C, Taylor-Robinson D. Chlamydia trachomatis and reactive arthritis: the missing link. Lancet 1987; i: 72–4
   Google Scholar
• Schumacher HR, Jr., Magge S, Varghese Cherian P., et al. Light and electron microscopic studies on the synovial membrane in Reiter's syndrome. Arthritis Rheum 1988; 31: 937–46
   PubMed Web of Science ®Google Scholar
• Lahesmaa-Rantala R, Granfors K, Isomaki H, Toivanen A. Yersinia specific immune complexes in the synovial fluid of patients with yersinia triggered reactive arthritis. Ann Rheum Dis 1987; 46: 510–4
   PubMed Web of Science ®Google Scholar
• Granfors K, Jalkanen S, von Essen R, et al. Yersinia antigens in synovial fluid cells from patients with reactive arthritis. N Engl J Med 1989; 320: 216–21
   PubMed Web of Science ®Google Scholar
• Granfors K, Jalkanen S. Lindberg AA, et al. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet 1990; 335: 685–8
   PubMed Web of Science ®Google Scholar
• Clarke J, Weiner S R, Bassett L W, Utsinger PD. Bypass disease. Clin Exp Rheumatol 1987; 5: 275–87
   PubMed Web of Science ®Google Scholar
• Serrander R, Magnusson K-E, Kihlstrom E, Sundqvist T. Acute yersinia infections in man increase intestinal permeability for low-molecular weight polyethylene glycols (PEG 400). Scand J Infect Dis 1986; 18: 409–13
   PubMed Web of Science ®Google Scholar
• Hollander D, Vadheim C M, Brettholz E, Petersen G, Delahunty M. T., Rotter J. Increased intestinal permeability in patients with Crohn's disease and their relatives. Ann Intern Med 1986; 105: 883–5
   PubMed Web of Science ®Google Scholar
• Smith M D, Gibson R A, Brooks PM. Abnormal bowel permeability in ankylosing spondylitis and rheumatoid arthritis. J Rheumatol 1985; 12: 299–305
   PubMed Web of Science ®Google Scholar
• Wright V, Watkinson G. The arthritis of ulcerative colitis. Br Med J 1965; 2: 670–5
   PubMed Web of Science ®Google Scholar
• De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A. Ileocolonoscopy in seronegative spondyloarthropathy. Gastroenterology 1989; 96: 339–44
   PubMed Web of Science ®Google Scholar
• Granfors K, Viljanen M, Tiilikainen A, Toivanen A. Persistence of IgM, IgG and IgA antibodies to yersinia in yersinia arthritis. J Infect Dis 1980; 141: 424–9
   PubMed Web of Science ®Google Scholar
• Granfors K., Toivanen A. IgA-anti-yersinia antibodies in yersinia triggered reactive arthritis. Ann Rheum Dis 1986; 45: 561–5
   PubMed Web of Science ®Google Scholar
• Toivanen A, Granfors K., Lahesmaa-Rantala R, Leino R, Stahlberg T., Vuento R. Pathogenesis of Yersinia-triggered reactive arthritis: Immunological, microbiological and clinical aspects. Immunol Rev 1985; 86: 47–70
   PubMed Web of Science ®Google Scholar
• Geczy A FMC, Guigan L E, Sullivan J S, Edmonds JP. Cytotoxic lymphocytes against disease-associated determinant(s) in ankylosing spondylitis. J Exp Med 1986; 164: 932–7
   PubMed Web of Science ®Google Scholar
• Schwimmbeck P L, Yu D TY, Oldstone M BA. Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. J Exp Med 1987; 1166: 173–81
   Google Scholar
• Stieglitz H, Fosmire S, Lipsky P. Identification of a 2-Md plasmid from Shigella flexneri associated with reactive arthritis. Arthritis Rheum 1989; 32: 937–46
   PubMedGoogle Scholar
• Chen J-H, Kono D H, Yong Z, Park M S, Oldstone M MBA, Yu D TY. A Yersinia pseudotuberculosis protein which cross-reacts with HLA-B27. J Immunol 1987; 139: 3003–11
   PubMed Web of Science ®Google Scholar
• Repo H, Leirisalo-Repo M, Skurnik M, Tiilikainen A. Neutrophil function and HLA-B27. Superoxide production and yersinicidal activity of neutrophils from patients with previous yersinia arthritis. Med Biol 1984; 62: 91–4
   PubMedGoogle Scholar
• Leirisalo M, Repo H, Tiilikainen A, Kosunen T U, Laitinen O. Chemotaxis in yersinia arthritis. HLA-B27 positive neutrophils show high stimulated motility in vitro. Arthritis Rheum 1980; 20: 1036–44
   Google Scholar
• Pease C T, Fordham J T, Currey H LF. Polymorphonuclear cell motility, ankylosing spondylitis, and HLA-B27. Ann Rheum Dis 1984; 43: 279–84
   PubMed Web of Science ®Google Scholar
• Pease C T, Fennell M, Brewerton DA. Polymorphonuclear leucocyte motility in men with ankylosing spondylitis. Ann Rheum Dis 1989; 48: 35–41
   PubMed Web of Science ®Google Scholar
• Koivuranta-Vaara P, Repo H, Leirisalo M, Kiistala U, Osterman T, Vapaatalo H. Enhanced neutrophil migration in vivo in HLA B27 positive subjects. Ann Rheum Dis 1984; 43: 181–5
   PubMed Web of Science ®Google Scholar
• Leirisalo-Repo M, Lauhio A, Repo H. Chemotaxis and chemiluminescence responses of synovial fluid polymorphonuclear leucocytes during acute reactive arthritis. Ann Rheum Dis 1990; 49: 615–9
   Google Scholar
• Miller C, Russell AS. The generation of superoxide anions by polymorphonuclear leucocytes from patients with ankylosing spondylitis in response to stimulant f-met-leu-phe. Clin Exp Rheumatol 1986; 4: 135–7
   PubMed Web of Science ®Google Scholar
• Koivuranta-Vaara P, Leirisalo-Repo M, Repo H. Polymorphonuclear leucocyte function and previous yersinia arthritis: enhanced chemokinetic migration and oxygen radical production correlate with the severity of the acute disease. Ann Rheum Dis 1987; 46: 307–13
   PubMed Web of Science ®Google Scholar
• Repo H, Koivuranta-Vaara P, Leirisalo-Repo M. Polymorphonuclear leucocyte function and previous yersinia arthritis: enhanced superoxide production correlates with late manifestations. Ann Rheum Dis 1988; 47: 452–7
   PubMed Web of Science ®Google Scholar
• Csonka GW. Recurrent attacks in Reiter's disease. Arthritis Rheum 1960; 3: 164–9
   PubMedGoogle Scholar
• Ristola M. Increased oxygen radical production determined by whole blood chemiluminescence in patients with previous yersinia arthritis. APMIS 1990; 98: 125–30
   Google Scholar
• Feltelius N, Hallgren R, Venge P. Raised circulating levels of the eosinophil cationic protein in ankylosing spondylitis: relation with the inflammatory activity and influence of sulphasalazine treatment. Ann Rheum Dis 1987; 46: 403–7
   PubMed Web of Science ®Google Scholar
• Repo H, Leirisalo M, Tiilikainen A, Laitinen O. Chemotaxis in yersinia arthritis. In vitro stimulation of neutrophil migration by HLA-B27 positive and negative sera. Arthritis Rheum 1982; 25: 655–61
   PubMed Web of Science ®Google Scholar
• Brinch L, Vinje O, Teisberg P, Mellbye O J, Aakesson I. The in-vivo metabolism of C3 in ankylosing spondylitis. Ann Rheum Dis 1982; 41: 86–9
   PubMed Web of Science ®Google Scholar
• Meri S, Partanen J, Leirisalo-Repo M, Repo H. Complement activation and HLA-B27. Ann Rheum Dis 1988; 47: 210–4
   PubMed Web of Science ®Google Scholar
• Repo H, Leirisalo-Repo M, Gripenberg M, Koskimies S, Kontiainen S, Laitinen O. Yersinia arthritis, immune functions and histocompatibility antigens. Acta Pathol Microbiol Immunol Scand Sect C 1986; 94: 245–52
   PubMedGoogle Scholar
• Repo H, Jaattela M, Leirisalo-Repo M, Hurme M. Production of tumour necrosis factor and interleukin 1 by monocytes of patients with previous yersinia arthritis. Clin Exp Immunol 1988; 72: 410–4
   PubMed Web of Science ®Google Scholar
• Speis T, Morton C C, Nedospasov S A, Fiers W, Pious D. Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc Natl Acad Sci 1986; 83: 8699–702
   PubMed Web of Science ®Google Scholar
• Marsal L, Winblad S, Wollheim FA. Yersinia enterocolitica arthritis in southern Sweden: a four-year follow-up study. Br Med J 1981; 283: 101–3
   PubMedGoogle Scholar
• Leirisalo-Repo M, Skylv G, Kousa M. Follow-up study of Reiter's disease and reactive arthritis. Factors influencing the natural course and the prognosis. Clin Rheumatol 1987; 6: 73–82, Suppl 2
   Google Scholar
• Zachariae H, From E, Zachariae E. Reiter's sygdom og prostatitis. Ugeskr Laeg 1979; 141: 2058–9
   Google Scholar
• Rosenthal L, Lagergren C, Olhagen B. A clinical and roentgenological follow-up study of patients with uro-arthritis or pelvospondylitis. Acta Rheum Scand 1971; 17: 3–14
   PubMedGoogle Scholar
• Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month lymecycline in reactive arthritis with special reference to chlamydia arthritis. Arthritis Rheum, in press
   Google Scholar
• Belsheim J, Gnarpe H, Persson S. Tetracyclines and host defence mechanisms: Interference with leucocyte chemotaxis. Scand J Infect Dis 1979; 11: 141–5
   PubMed Web of Science ®Google Scholar
• Greenwald R A, Golub L M, Lavietes B, et al. Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol 1987; 14: 28–32
   PubMed Web of Science ®Google Scholar
• Sairanen E, Paronen I, Mahonen H. Reiter's syndrome: a follow-up study. Acta Med Scand 1969; 185: 57–63
   PubMedGoogle Scholar
• Leirisalo-Repo M, Suoranta H. Ten-year follow-up study of patients with Yersinia arthritis. Arthritis Rheum 1988; 31: 533–7
   PubMed Web of Science ®Google Scholar
• Leirisalo M, Skylv G, Kousa M, et al. Follow-up study on patients with Reiter's disease and reactive arthritis, with special reference to HLA-B27. Arthritis Rheum 1982; 25: 249–59
   PubMed Web of Science ®Google Scholar
• Fox R, Calin A, Gerber R C, Gibson D. The chronicity of symptoms and disability in Reiter's syndrome. Ann Intern Med 1979; 91: 190–3
   PubMed Web of Science ®Google Scholar
• Mielants H, Veys E M, Joos R. Sulphasalazine (salazopyrin) in the treatment of enterogenic reactive arthritis and ankylosing spondylitis with peripheral arthritis. Clin Rheumatol 1986; 5: 80–3
   PubMedGoogle Scholar
• Feltelius N, Hallgren R. Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 1986; 45: 396–9
   PubMedGoogle Scholar
• Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J 1986; 293: 911–4
   PubMed Web of Science ®Google Scholar
• Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988; 31: 1111–6
   PubMed Web of Science ®Google Scholar
• Suematsu M, Suzuki M, Miura S, et al. Sulfasalazine and its metabolites attenuate respiratory burst of leukocytes—a possible mechanism of anti-inflammatory effects. J Clin Lab Immunol 1987; 23: 31–3
   PubMedGoogle Scholar
• Stenson W F, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 1982; 69: 494–7
   PubMed Web of Science ®Google Scholar
• Remvig L. Sulfasalazine inhibition of endotoxin induced interleukin-1 production from human monocytes in vitro. Scand J Immunol 1988; 28: 507
   Google Scholar